The Integra Vu aPOD-L. Intervertebral Body Fusion Device is indicated for use as an adjunct to fusion in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade 1 spondylolisthesis at the involved level(s). The device is to be packed with autogenous bone graft (i.e. autograft). The Integra Vu aPOD-L Intervertebral Body Fusion Device is intended for use with supplemental fixation that is in addition to the integrated buttress spin plate, such as a pedicle screw system or anterior plate.

Degenerative disc disease is defined as back pain of discogenic origin, with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of nonoperative treatment.

Device Description

The Integra Vu aPOD-L. Intervertebral Body Fusion Device consists of spinal fusion cages, optional internal buttress plates, as well as instrumentation designed specifically for the implantation of these devices. The spinal fusion cages are offered in heights of 8-16mm, lengths of 44-64mm, widths of 18mm and 23mm, and lordotic angled geometries to accommodate variations in patient anatomy. The cages include teeth on the top and bottom surfaces to engage with the superior and inferior end plates of neighboring vertebral bodies to resist rotation and migration. The cages contain an open central channel for receiving bone graft to allow for bony in-growth in and around the implant. The cages can be used in combination with an optional titanium spin plate and contain radiographic markers. The devices are manufactured from Polyetheretherketone (PEEK-OPTIMA LT-1) per ASTM F2026, Titanium alloy (Ti-6Al-4V ELI) per ASTM F136, and Tantalum per ASTM F560.

AI/ML Overview

The provided document (K112986 for the Integra Vu aPOD-L Intervertebral Body Fusion Device) is a 510(k) summary, which focuses on demonstrating substantial equivalence to a predicate device rather than presenting a study with acceptance criteria for a novel device. Therefore, much of the requested information regarding acceptance criteria and performance studies in the context of AI/ML devices or clinical trials is not explicitly available in this type of submission.

However, I can extract the relevant information from the document as it pertains to the device's "performance" in the context of a 510(k) submission.

1. A table of acceptance criteria and the reported device performance:

In the context of this 510(k), "acceptance criteria" are analogous to the successful completion of specified mechanical tests to demonstrate that the device performs equivalently to the predicate.

Acceptance Criteria (Mechanical Testing)	Reported Device Performance
Performed per ASTM F2077 (static axial compression)	Demonstrated substantial equivalence to predicate device (K080822).
Performed per ASTM F2077 (static compress-shear)	Demonstrated substantial equivalence to predicate device (K080822).
Performed per ASTM F2077 (dynamic axial compression)	Demonstrated substantial equivalence to predicate device (K080822).
Performed per ASTM F2267 (static subsidence)	Demonstrated substantial equivalence to predicate device (K080822).
Performed expulsion testing as part of standard design control activity	Demonstrated substantial equivalence to predicate device (K080822).

2. Sample size used for the test set and the data provenance:

Sample Size for Test Set: Not applicable in the context of this mechanical testing. The standards specify how many samples of the device components should be tested to meet the ASTM standards. This information is not detailed in the 510(k) summary but would be part of the full design control documentation.
Data Provenance: The data comes from in vitro mechanical testing performed by the manufacturer, Integra Spine, LLC, based in Medina, OH, USA. This is not retrospective or prospective clinical data but rather laboratory-generated data.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

This is not applicable. The "ground truth" for mechanical testing is established by the specified ASTM standards and the measurements obtained during testing against those standards. No expert consensus is involved in defining the physical properties and performance metrics of the device in this context.

4. Adjudication method for the test set:

Not applicable. Mechanical testing results are objective measurements against predefined standards.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

Not applicable. This device is an intervertebral body fusion device and does not involve AI or human readers in its function. No MRMC study was performed.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

Not applicable. This device is not an algorithm.

7. The type of ground truth used:

For the mechanical performance, the "ground truth" is defined by adherence to the performance criteria outlined in the ASTM standards (ASTM F2077, ASTM F2267) and successful demonstration of functional equivalence to the predicate device.

8. The sample size for the training set:

Not applicable. This device did not involve machine learning; therefore, there was no "training set."

9. How the ground truth for the training set was established:

Not applicable. No training set was used.

Summary

{0}------------------------------------------------

MAY - 1 2012

Manufacturer:	Integra Spine, LLC1153 Medina RoadMedina, OH 44256Phone: 330 239 7700Fax: 330 239 4216
Contact:	Dale DavisonVice President of EngineeringIntegra Spine, LLC1153 Medina RoadMedina, OH 44256Office.: 330-239-7709Fax: 330-239-4216Email: dale.davison@integralife.com
Date Prepared:	April 18, 2012
Device Trade Name:	Integra Vu aPOD-L Intervertebral Body Fusion Device
Classification:	§888.3080, Intervertebral body fusion device
Class:	II
Product Code:	OVD, MAX
Predicate Device:	Theken Spine Vu aPOD Intervertebral Body FusionDevice (K080822)

Device Description:

510(k) Summary

{1}------------------------------------------------

Indications For Use:

Substantial Equivalence Comparison:

The technological characteristics of the Integra Vu aPOD-L Intervertebral Body Fusion Device are the same as the predicate device Theken Spine Vu aPOD Intervertebral Body Fusion Device (K080822).

The subject device similarities include:

The same indications for use .
The same basic design .
The same materials .
Used in conjunction with supplemental fixation .
The same sterilization process .
The same packaging configurations .

Performance Standards:

Mechanical testing was performed per ASTM F2077 (static axial compression, static compress-shear, dynamic axial compression). ASTM F2267 (static subsidence) and expulsion as part of standard design control activity, demonstrating that the Integra Vu aPOD-L Intervertebral Body Fusion Device is substantially equivalent to the predicate device.

Clinical Testing:

There was no clinical or animal testing performed for this submission.

Conclusion:

Integra Spine believes that sufficient information has been presented to demonstrate that the Integra Vu aPOD-L Intervertebral Body Fusion Device is substantially equivalent to the predicate device with respect to safety, efficacy and performance, and has the same indications, intended use, and technological features to the legally marketed device listed.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a stylized eagle with three tail feathers, representing the three levels of government: federal, state, and local. The eagle is encircled by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

Integra Spine, LLC % Mr. Dale Davison Vice President of Engineering 1153 Medina Road Medina, Ohio 44256

MAY - 1 2012

Re: K112986

Trade/Device Name: Integra Vu aPOD-L Intervertebral Body Fusion Device Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: OVD, MAX Dated: April 18, 2012 Received: April 20, 2012

Dear Mr. Davison:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 - Mr. Dale Davison

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please 11 you active pps.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Mark N. Mikkelson

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

{4}------------------------------------------------

Statement of Indications For Use

510(k) Number (if known): K112986

Indications For Use:

The Integra Vu aPOD-L Intervertebral Body Fusion Device is indicated for use as an adjunct to fusion in patients with degenerative disc disease (DDD) at one or two contiquous levels from L2 to S1. These DDD patients may also have up to Grade 1 spondylolisthesis at the involved level(s). The device is to be packed with autogenous bone graft (i.e. autograft). The Integra Vu aPOD-L Intervertebral Body Fusion Device is intended for use with supplemental fixation that is in addition to the integrated buttress spin plate, such as a pedicle screw system or anterior plate.

ج Prescription Use (Part 29 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (29 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Surgical, Orthopedic, and Restorative Devices

K112986 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------510(k) Number_

Regulation Number and Section

§ 888.3080 Intervertebral body fusion device.

(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.